idoxuridine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
uridine derivatives used as antiviral agents and as antineoplastics 1417 54-42-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • idoxuridine
  • iododeoxyuridine
  • allergan
  • idoxene
  • idoxuridin
An analog of DEOXYURIDINE that inhibits viral DNA synthesis. The drug is used as an antiviral agent.
  • Molecular weight: 354.10
  • Formula: C9H11IN2O5
  • CLOGP: -0.42
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 3
  • TPSA: 99.10
  • ALOGS: -1.18
  • ROTB: 2
  • Status: OFM
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,ITK,JAK2,JAK3,MAP2K6,MAP3K21,MAP3K7,MAP4K1,MAPK10,MAPK7,MAPK9,MET,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CD,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ZAP70 47
kinase-selectivity-class AXL,CDK9,GRK2,IRAK1,MAP2K6,MAP3K14,PDK1,PRKDC,TEK 9
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 0 Moderate 0.74

Approvals:

DateAgencyCompanyOrphan
June 11, 1963 FDA ALLERGAN

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC D06BB01 DERMATOLOGICALS
ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE
CHEMOTHERAPEUTICS FOR TOPICAL USE
Antivirals
ATC J05AB02 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Nucleosides and nucleotides excl. reverse transcriptase inhibitors
ATC S01AD01 SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIINFECTIVES
Antivirals
FDA EXT N0000175459 Nucleoside Analog
FDA EPC N0000175466 Nucleoside Analog Antiviral
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000998 Antiviral Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D019384 Nucleic Acid Synthesis Inhibitors
CHEBI has role CHEBI:36044 antiviral drugs
CHEBI has role CHEBI:59517 DNA synthesis inhibitors

Related Drugs by ATC class:

D06BB Antivirals 11 drugs
acyclovirberdazimerdocosanoledoxudineibacitabineimiquimodinosinepenciclovirpodophyllotoxinsinecatechinstromantadine
J05AB Nucleosides and nucleotides excl. reverse transcriptase inhibitors 11 drugs
acyclovirbrivudinecidofovirfamciclovirganciclovirmolnupiravirpenciclovirremdesivirvalaciclovirvalganciclovirvidarabine
S01AD Antivirals 6 drugs
acyclovirfamciclovirfomivirsenganciclovirtrifluridinevidarabine

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Herpes simplex keratitis indication 9389005
Vaccinia keratitis off-label use 397552005




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.03 acidic
pKa2 13.02 acidic
pKa3 13.7 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Thymidine kinase, cytosolic Kinase Ki 7.05 CHEMBL
Thymidine kinase Kinase IC50 5.82 CHEMBL

External reference:

IDSource
4018015 VUID
N0000146359 NUI
D00342 KEGG_DRUG
4018015 VANDF
C0020811 UMLSCUI
CHEBI:147675 CHEBI
CHEMBL788 ChEMBL_ID
DB00249 DRUGBANK_ID
D007065 MESH_DESCRIPTOR_UI
5905 PUBCHEM_CID
1486 INN_ID
LGP81V5245 UNII
360903 RXNORM
4866 MMSL
003011 NDDF
373499006 SNOMEDCT_US
49705006 SNOMEDCT_US
ID2 PDB_CHEM_ID

Pharmaceutical products:

None